TBR1 and Hepatic fibrosis: The AAV-TβR1 0W group and combination therapy group exhibited significant treatment effects towards hepatic fibrosis in rats, as shown by a significant reduction in liver stiffness compared to the model group (p < 0.01); the pathological results also indicated a decrease in the degree of hepatic fibrosis (Fig 6B).